Atlas Trials

Lymphoma, Large-Cell, Anaplastic

17 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Lymphoma, Large-Cell, Anaplastic

RecordFirmDate
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (NCT05106192)Case Comprehensive Cancer Center2022-04-01
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation (NCT03942263)Takeda2019-05-31
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas (NCT03049449)National Cancer Institute (NCI)2017-03-17
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) (NCT02939014)Takeda2016-11-07
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267)Hoffmann-La Roche2015-11-19
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) (NCT01449461)Ariad Pharmaceuticals2011-09-20
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms (NCT01309789)Seagen Inc.2011-02-01
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) (NCT01026233)Seagen Inc.2010-01-01
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) (NCT01026415)Seagen Inc.2009-12-01
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study (NCT00947856)Seagen Inc.2009-07-01
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma (NCT00866047)Seagen Inc.2009-03-01
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies (NCT00649584)Seagen Inc.2008-03-01
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies (NCT00430846)Seagen Inc.2006-11-01
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 (NCT01196208)Seagen Inc.

Track Lymphoma, Large-Cell, Anaplastic automatically

Every clearance here is in the API, with alerts when new ones post.